Preclinical characterization of a novel therapeutic antibody targeting LILRB2

Written By Mollie Rotmensch

Costa M. et al. The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting & Pre-Conference Programs (SITC 2020), Virtual. November 9-14, 2020.

Mollie Rotmensch
Previous

A First-in-Human Phase 1 Study of the Anti-LILRB4 Antibody IO-202…

Next

LILRB4-targeting Antibody–Drug Conjugates for the Treatment of Acute Myeloid Leukemia